Physician profile
Gerami Donyel Seitzman
NPI 1326081977
$110,891.17
in general payments reported to CMS, 2019-2025
4 companies · $34K in 2025
The $34K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.63 · 2020: $11K · 2021: $9,600 · 2023: $750 · 2024: $55K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $86K · Travel and Lodging: $2,931 · Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $86,135.95 |
| Travel and Lodging | $2,930.92 |
| Food and Beverage | $749.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedrion Biopharma, INC. | $63,613.33 | 2024-2025 | Albuked, Koate, Gammaked |
| Dompe US, INC. | $39,728.15 | 2019-2025 | Oxervate |
| Dompe Farmaceutici S.P.A. | $5,257.05 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $2,292.64 | 2024-2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerami Seitzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.